CA2965185A1 - Method and composition for treating ocular hypertension and glaucoma - Google Patents

Method and composition for treating ocular hypertension and glaucoma Download PDF

Info

Publication number
CA2965185A1
CA2965185A1 CA2965185A CA2965185A CA2965185A1 CA 2965185 A1 CA2965185 A1 CA 2965185A1 CA 2965185 A CA2965185 A CA 2965185A CA 2965185 A CA2965185 A CA 2965185A CA 2965185 A1 CA2965185 A1 CA 2965185A1
Authority
CA
Canada
Prior art keywords
tafluprost
ophthalmic
glaucoma
analogues
preservatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2965185A
Other languages
English (en)
French (fr)
Inventor
Timo Reunamaki
Pertti Pellinen
Olli Oksala
Kari Lehmussaari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
AGC Inc
Original Assignee
Asahi Glass Co Ltd
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39940592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2965185(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asahi Glass Co Ltd, Santen Pharmaceutical Co Ltd filed Critical Asahi Glass Co Ltd
Publication of CA2965185A1 publication Critical patent/CA2965185A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2965185A 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma Abandoned CA2965185A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08397513A EP2127638A1 (en) 2008-05-30 2008-05-30 Method and composition for treating ocular hypertension and glaucoma
EP08397513.6 2008-05-30
CA2724194A CA2724194C (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2724194A Division CA2724194C (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma

Publications (1)

Publication Number Publication Date
CA2965185A1 true CA2965185A1 (en) 2009-12-03

Family

ID=39940592

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2724194A Active CA2724194C (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma
CA2965185A Abandoned CA2965185A1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2724194A Active CA2724194C (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma

Country Status (27)

Country Link
US (3) US9999593B2 (enExample)
EP (8) EP2127638A1 (enExample)
JP (9) JP2011521943A (enExample)
KR (5) KR101650006B1 (enExample)
CN (1) CN102083413B (enExample)
AR (2) AR071937A1 (enExample)
AU (1) AU2009252210C1 (enExample)
BR (1) BRPI0913109B8 (enExample)
CA (2) CA2724194C (enExample)
CY (2) CY1115565T1 (enExample)
DK (4) DK3714877T3 (enExample)
EA (1) EA023661B1 (enExample)
ES (6) ES2907982T3 (enExample)
GE (1) GEP20156220B (enExample)
HR (4) HRP20220361T1 (enExample)
HU (3) HUE049923T2 (enExample)
JO (1) JO3039B1 (enExample)
LT (3) LT3714877T (enExample)
MX (1) MX2010012987A (enExample)
MY (1) MY159463A (enExample)
PL (4) PL3205334T3 (enExample)
PT (4) PT2772249T (enExample)
SG (1) SG191628A1 (enExample)
SI (4) SI3205334T1 (enExample)
TW (1) TWI432202B (enExample)
UA (1) UA102257C2 (enExample)
WO (1) WO2009145356A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
EP2389939A1 (en) 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
JP5681472B2 (ja) * 2009-12-28 2015-03-11 ロート製薬株式会社 眼科用組成物
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US10154923B2 (en) * 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
CA2806973A1 (en) * 2010-07-29 2012-02-02 Allergan, Inc. Preservative free bimatoprost solutions
US9061034B2 (en) * 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
EP2598118B1 (en) * 2010-07-29 2018-09-05 Allergan, Inc. Preservative free bimatoprost and timolol solutions
WO2012021107A2 (en) 2010-08-12 2012-02-16 Nanyang Technological University A liposomal formulation for ocular drug delivery
WO2012038469A2 (en) * 2010-09-21 2012-03-29 S&V Technologies Ag Cosmetic composition
EP2452669A1 (en) * 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
EP2696876A4 (en) * 2011-04-12 2014-09-03 R Tech Ueno Ltd AQUEOUS OPHTHALMIC COMPOSITION
CN102716074B (zh) * 2012-06-28 2013-10-16 武汉武药科技有限公司 一种贝美前列素滴眼剂及其制备方法
US8980839B2 (en) * 2012-08-24 2015-03-17 Ocular Technologies Sarl Topical aqueous nanomicellar, ophthalmic solutions and uses thereof
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
CA2935957C (en) 2014-01-10 2023-01-03 Manistee Partners Llc Treatment of migraines using topical administration of prostaglandin f2alpha analogs
CN104766952B (zh) * 2015-04-21 2017-01-25 武汉凯迪工程技术研究总院有限公司 利用生物质气化炉滤渣制备锂离子电池负极材料的方法
ES2747302T3 (es) 2015-06-09 2020-03-10 Medproject Pharma Entw Und Vertriebsgesellschaft Mbh Gel oftálmico de bimatoprost aplicable en gotas
US10105371B2 (en) * 2015-10-09 2018-10-23 Tamara Vrabec Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject
US20180325854A1 (en) * 2015-11-06 2018-11-15 Accuitis Pharmaceuticals, Inc. Use of proteasome inhibitors to treat ocular disorders
WO2017083167A1 (en) 2015-11-10 2017-05-18 Ocular Technologies Sarl Topical formulations and uses thereof
NZ785158A (en) 2016-02-29 2025-03-28 Sun Pharmaceutical Ind Ltd Topical cyclosporine-containing formulations and uses thereof
GR1009040B (el) * 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
WO2018033854A1 (en) * 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
KR101770324B1 (ko) * 2016-11-09 2017-08-22 주식회사태준제약 안압 강하용 점안 조성물
JP2020059652A (ja) * 2016-12-26 2020-04-16 参天製薬株式会社 タフルプロストとクエン酸エステルとを含有するデポ剤
EP4285908A3 (en) * 2017-03-27 2024-02-14 Alcon Inc. Pharmaceutical preparation
US20180318319A1 (en) * 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
US11382887B2 (en) 2017-06-22 2022-07-12 Ys Life Science Co. Ltd. Ophthalmic composition for glaucoma treatment
ES3041644T3 (en) * 2017-12-21 2025-11-13 Santen Pharmaceutical Co Ltd Combination of sepetaprost and netarsudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
EA202190214A1 (ru) 2018-07-09 2021-04-16 Варшавске Закляды Фармацеутычне Польфа Са Офтальмологическое дозирующее устройство
JP7599838B2 (ja) * 2019-04-10 2024-12-16 参天製薬株式会社 エピナスチン又はその塩を含有する水性医薬組成物
CN111632025A (zh) * 2020-03-04 2020-09-08 吉林大学第一医院 一种贝美前列素眼用温度敏感型原位凝胶及其制备方法与应用
CN111840225B (zh) * 2020-08-12 2021-09-14 陈丽娜 一种用于治疗青光眼的滴眼剂及其制备方法
RU2761625C2 (ru) * 2021-02-11 2021-12-13 Общество с ограниченной ответственностью "Гротекс" (ООО "Гротекс") Фармацевтическая композиция тафлупроста
CN116687842A (zh) * 2022-02-28 2023-09-05 山东新时代药业有限公司 一种拉坦前列素滴眼液及其制备方法
JPWO2023182480A1 (enExample) * 2022-03-25 2023-09-28
CN119384280A (zh) * 2022-06-16 2025-01-28 广州润尔眼科生物科技有限公司 一种药物组合物及其制备方法和应用
WO2024203727A1 (ja) * 2023-03-24 2024-10-03 株式会社坪田ラボ 水性組成物
WO2024232425A1 (ja) * 2023-05-11 2024-11-14 テイカ製薬株式会社 プロスタグランジンＦ２α誘導体の含有率低下が抑制されている製品
JP7757564B1 (ja) * 2024-06-28 2025-10-21 東亜薬品株式会社 水性組成物

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778815A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of inhibiting cataracts by topical application of a 2-substituted 1,2-benzisoselenazol-3(2H)-one
ES2042625T5 (es) 1987-04-03 2000-07-16 Univ Columbia Uso de una prostaglandina en combinacion con un agente bloqueante adrenergico para la reduccion de presion intraocular.
US5409125A (en) 1989-12-11 1995-04-25 Aktiebolaget Astra Unit dose container
DE4027320C2 (de) 1990-08-29 1993-09-30 Ursapharm Arzneimittel Gmbh Fluid-Abgabeeinrichtung für keimfreies Fluid
JPH0655640A (ja) 1992-08-04 1994-03-01 Aavan Internatl:Kk 洗面台カウンター及びその製造方法
JPH06107547A (ja) 1992-10-01 1994-04-19 Aarutetsuku Ueno:Kk 眼科用組成物
AU665287B2 (en) 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
JP2510066Y2 (ja) 1993-01-20 1996-09-11 東洋製罐株式会社 加熱殺菌可能な液体医薬容器
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
CA2237898A1 (en) * 1995-11-17 1997-05-29 Louis Desantis Jr. Combination therapy for treating glaucoma
ATE221048T1 (de) 1996-09-17 2002-08-15 Asahi Glass Co Ltd Fluorierte prostaglandinderivate und medikamente
JP2001505855A (ja) 1996-12-09 2001-05-08 ボシュ アンド ロム インコーポレイテッド 使い捨て可撓容器
JP3480549B2 (ja) 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
EP0979652B1 (en) * 1997-10-13 2006-05-24 R-Tech Ueno, Ltd. Remedial composition for intraocular hypertension or glaucoma
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
GB2337740B (en) 1998-05-26 2000-11-15 Spreckelsen Mcgeough Ltd Fluid packaging
BR9906597A (pt) 1998-07-14 2000-07-18 Alcon Lab Inc Produto de prostaglandina
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
AU761785B2 (en) 1998-09-25 2003-06-12 Alcon Laboratories, Inc. Sustained release, and comfortable ophthalmic composition and method for ocular therapy
US6096783A (en) 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
EP1905757A1 (en) 1999-04-06 2008-04-02 Sepracor Inc. Derivatives of Venlafaxine and methods of preparing and using the same
WO2001097852A1 (en) 2000-06-19 2001-12-27 Santen Pharmaceutical Co., Ltd. Aseptics
JP3876355B2 (ja) * 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
KR100854056B1 (ko) 2000-09-13 2008-08-26 산텐 세이야꾸 가부시키가이샤 점안액
TW586946B (en) 2000-12-22 2004-05-11 Novartis Ag Process to improve stability
WO2004006826A1 (ja) 2002-07-16 2004-01-22 Senju Pharmaceutical Co., Ltd. 薬液容器及びその製造方法
WO2004022063A1 (ja) 2002-09-09 2004-03-18 Santen Pharmaceutical Co., Ltd. ラタノプロストを有効成分とする澄明な点眼液
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
EP1666043B1 (en) 2003-07-31 2009-12-02 Santen Pharmaceutical Co., Ltd. Product containing prostaglandin
US20050287325A1 (en) 2004-06-25 2005-12-29 Pharmacia & Upjohn Company Pharmaceutical containers with low adsorption/absorption of active ingredients, and a method of testing materials for adsorption/absorption of active ingredients
ES2314354T3 (es) * 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
US7562796B2 (en) 2004-11-24 2009-07-21 Holopack International Corp. Dispensing container with flow control system
CN102526064A (zh) 2004-12-09 2012-07-04 参天制药株式会社 含有分子内具有氟原子的前列腺素的制品
EP1829545B1 (en) 2004-12-24 2012-05-02 Santen Pharmaceutical Co., Ltd. Prostaglandin f2 alpha derivative containing products
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
PT1905453E (pt) 2005-07-13 2012-12-04 Santen Pharmaceutical Co Ltd Composição conservante para utilização oftálmica
ES2460967T3 (es) * 2005-08-02 2014-05-16 Santen Pharmaceutical Co., Ltd. Método para la prevención de la degradación de una sustancia térmicamente inestable
PT1937212E (pt) 2005-10-10 2010-11-30 Novagali Pharma Sa Emulsões oftálmicas contendo prostaglandinas
FI126233B (sv) 2006-02-23 2016-08-31 Oy Kwh Mirka Ab Oscillerande slipmaskin
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
KR100927617B1 (ko) 2007-11-26 2009-11-23 한국표준과학연구원 열분해 탄소 성분의 나노 크기를 가지는 바이오 센서의감지부를 제작하는 방법
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma

Also Published As

Publication number Publication date
ES2808050T3 (es) 2021-02-25
KR101988642B1 (ko) 2019-06-12
JP2024079852A (ja) 2024-06-11
JP6356868B2 (ja) 2018-07-11
JP2021120412A (ja) 2021-08-19
JP6889789B2 (ja) 2021-06-18
JP2014133765A (ja) 2014-07-24
EP3205334B1 (en) 2020-04-29
JP7265584B2 (ja) 2023-04-26
HUE033103T2 (en) 2017-11-28
ES2968837T3 (es) 2024-05-14
LT2772249T (lt) 2017-09-11
DK2306977T3 (da) 2014-09-15
JP7520285B2 (ja) 2024-07-23
PL2306977T3 (pl) 2015-01-30
EP4035656B1 (en) 2023-11-22
LT3714877T (lt) 2022-04-11
KR20190067272A (ko) 2019-06-14
TW201000104A (en) 2010-01-01
SI2306977T1 (sl) 2014-12-31
SI3205334T1 (sl) 2020-10-30
EP4289446A2 (en) 2023-12-13
JP6649992B2 (ja) 2020-02-19
JO3039B1 (ar) 2016-09-05
US20180289618A1 (en) 2018-10-11
DK3205334T3 (da) 2020-07-13
EP2772249B1 (en) 2017-05-03
DK2772249T3 (en) 2017-07-17
CY1120351T1 (el) 2019-07-10
SG191628A1 (en) 2013-07-31
KR102246598B1 (ko) 2021-04-30
PT3205334T (pt) 2020-07-31
EP4289446B1 (en) 2025-02-12
PL3205334T3 (pl) 2020-11-02
PT2772249T (pt) 2017-08-08
HUE058079T2 (hu) 2022-06-28
EP3205334A1 (en) 2017-08-16
DK3714877T3 (da) 2022-02-14
AR120961A2 (es) 2022-04-06
CN102083413B (zh) 2013-11-06
WO2009145356A1 (en) 2009-12-03
ES2627837T3 (es) 2017-07-31
SI3714877T1 (sl) 2022-05-31
BRPI0913109A2 (pt) 2017-06-20
CA2724194C (en) 2017-06-27
HRP20140979T1 (hr) 2014-11-21
US10864159B2 (en) 2020-12-15
EA201071413A1 (ru) 2011-06-30
HUE049923T2 (hu) 2020-11-30
AU2009252210A1 (en) 2009-12-03
US20210059931A1 (en) 2021-03-04
KR20110011707A (ko) 2011-02-08
US20110152264A1 (en) 2011-06-23
EP4289446A3 (en) 2024-01-10
ES3014089T3 (en) 2025-04-16
UA102257C2 (uk) 2013-06-25
JP2016065095A (ja) 2016-04-28
EP4035656A1 (en) 2022-08-03
KR20160102319A (ko) 2016-08-29
PT2306977E (pt) 2014-09-22
HRP20220361T1 (hr) 2022-05-13
EP2772249A1 (en) 2014-09-03
JP2017178957A (ja) 2017-10-05
EP3714877B1 (en) 2022-01-26
HRP20170769T1 (hr) 2017-08-11
BRPI0913109B8 (pt) 2021-05-25
KR101820816B1 (ko) 2018-01-22
CN102083413A (zh) 2011-06-01
HRP20200998T1 (hr) 2020-10-16
JP6148317B2 (ja) 2017-06-14
MX2010012987A (es) 2011-02-24
EP3714877A1 (en) 2020-09-30
MY159463A (en) 2017-01-13
JP2023085558A (ja) 2023-06-20
EA023661B1 (ru) 2016-06-30
US9999593B2 (en) 2018-06-19
KR20200057801A (ko) 2020-05-26
PT3714877T (pt) 2022-03-10
ES2907982T3 (es) 2022-04-27
AU2009252210B2 (en) 2014-10-16
TWI432202B (zh) 2014-04-01
EP2306977A1 (en) 2011-04-13
BRPI0913109B1 (pt) 2019-10-22
ES2495316T3 (es) 2014-09-17
EP4512424A2 (en) 2025-02-26
GEP20156220B (en) 2015-01-26
LT3205334T (lt) 2020-09-25
CY1115565T1 (el) 2017-01-04
EP2127638A1 (en) 2009-12-02
EP4512424A3 (en) 2025-03-05
JP2018154656A (ja) 2018-10-04
KR20180008905A (ko) 2018-01-24
PL3714877T3 (pl) 2022-05-16
SI2772249T1 (sl) 2017-08-31
JP2011521943A (ja) 2011-07-28
CA2724194A1 (en) 2009-12-03
AU2009252210C1 (en) 2016-04-14
JP2020073574A (ja) 2020-05-14
KR101650006B1 (ko) 2016-08-22
AR071937A1 (es) 2010-07-28
EP2306977B1 (en) 2014-08-13
PL2772249T3 (pl) 2017-10-31
KR102114401B1 (ko) 2020-05-25
ES2627837T8 (es) 2018-02-26

Similar Documents

Publication Publication Date Title
JP7265584B2 (ja) 高眼圧症及び緑内障を治療するための方法及び組成物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170425

FZDE Discontinued

Effective date: 20191024